The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2021 Feb 17

PMID 33594533

Citations 12

Authors

Carrie R Jonak

Manbir S Sandhu

Samantha A Assad

Jacqueline A Barbosa

Mahindra Makhija

Devin K Binder

Affiliations

Soon will be listed here.

Abstract

Fragile X syndrome (FXS) is a genetic neurodevelopmental syndrome characterized by increased anxiety, repetitive behaviors, social communication deficits, delayed language development, and abnormal sensory processing. Recently, we have identified electroencephalographic (EEG) biomarkers that are conserved between the mouse model of FXS (Fmr1 KO mice) and humans with FXS. In this study, we test a specific candidate mechanism for engagement of multielectrode array (MEA) EEG biomarkers in the FXS mouse model. We administered TAK-063, a potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor, to Fmr1 KO mice, and examined its effects on MEA EEG biomarkers. We demonstrate significant dose-related amelioration of inter-trial phase coherence (ITPC) to temporally modulated auditory stimuli by TAK-063 in Fmr1 KO mice. Our data suggest that TAK-063 improves cortical auditory stimulus processing in Fmr1 KO mice, without significantly depressing baseline EEG power or causing any noticeable sedation or behavioral side effects. Thus, the PDE10A inhibitor TAK-063 has salutary effects on normalizing EEG biomarkers in a mouse model of FXS and should be pursued in further translational treatment development.

Citing Articles

Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome.

Ethridge L, Pedapati E, Schmitt L, Norris J, Auger E, De Stefano L Sci Rep. 2024; 14(1):22982.

PMID: 39362936 PMC: 11450163. DOI: 10.1038/s41598-024-72935-6.

An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs.

Sudhahar S, Ozer B, Chang J, Chadwick W, ODonovan D, Campbell A Nat Commun. 2024; 15(1):5703.

PMID: 38977662 PMC: 11231212. DOI: 10.1038/s41467-024-50024-6.

Adult Inception of Ketogenic Diet Therapy Increases Sleep during the Dark Cycle in C57BL/6J Wild Type and Fragile X Mice.

Westmark P, Swietlik T, Runde E, Corsiga B, Nissan R, Boeck B Int J Mol Sci. 2024; 25(12).

PMID: 38928388 PMC: 11203515. DOI: 10.3390/ijms25126679.

State-of-the-art therapies for fragile X syndrome.

Protic D, Hagerman R Dev Med Child Neurol. 2024; 66(7):863-871.

PMID: 38385885 PMC: 11144093. DOI: 10.1111/dmcn.15885.

Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome.

Ethridge L, Pedapati E, Schmitt L, Norris J, Auger E, De Stefano L Res Sq. 2024; .

PMID: 38313274 PMC: 10836101. DOI: 10.21203/rs.3.rs-3849272/v1.

References

Crawford D, ACUNA J, Sherman S . FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med. 2001; 3(5):359-71. PMC: 4493892. DOI: 10.1097/00125817-200109000-00006. View

Yu S, Pritchard M, Kremer E, Lynch M, Nancarrow J, Baker E . Fragile X genotype characterized by an unstable region of DNA. Science. 1991; 252(5009):1179-81. DOI: 10.1126/science.252.5009.1179. View

Darnell J, Van Driesche S, Zhang C, Sharon Hung K, Mele A, Fraser C . FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011; 146(2):247-61. PMC: 3232425. DOI: 10.1016/j.cell.2011.06.013. View

Berry-Kravis E . Epilepsy in fragile X syndrome. Dev Med Child Neurol. 2002; 44(11):724-8. DOI: 10.1017/s0012162201002833. View

Hagerman R, Berry-Kravis E, Kaufmann W, Ono M, Tartaglia N, Lachiewicz A . Advances in the treatment of fragile X syndrome. Pediatrics. 2009; 123(1):378-90. PMC: 2888470. DOI: 10.1542/peds.2008-0317. View

Miller L, McIntosh D, McGrath J, Shyu V, Lampe M, Taylor A . Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet. 1999; 83(4):268-79. View

Musumeci S, Hagerman R, Ferri R, Bosco P, Dalla Bernardina B, Tassinari C . Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia. 1999; 40(8):1092-9. DOI: 10.1111/j.1528-1157.1999.tb00824.x. View

Sabaratnam M, Vroegop P, Gangadharan S . Epilepsy and EEG findings in 18 males with fragile X syndrome. Seizure. 2001; 10(1):60-3. DOI: 10.1053/seiz.2000.0492. View

Sinclair D, Oranje B, Razak K, Siegel S, Schmid S . Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models. Neurosci Biobehav Rev. 2016; 76(Pt B):235-253. PMC: 5465967. DOI: 10.1016/j.neubiorev.2016.05.029. View

10.

van der Molen M, Huizinga M, Huizenga H, Ridderinkhof K, van der Molen M, Hamel B . Profiling Fragile X Syndrome in males: strengths and weaknesses in cognitive abilities. Res Dev Disabil. 2009; 31(2):426-39. DOI: 10.1016/j.ridd.2009.10.013. View

11.

Wisniewski K, Segan S, Miezejeski C, SERSEN E, Rudelli R . The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. Am J Med Genet. 1991; 38(2-3):476-80. DOI: 10.1002/ajmg.1320380267. View

12.

Castren M, Paakkonen A, Tarkka I, Ryynanen M, Partanen J . Augmentation of auditory N1 in children with fragile X syndrome. Brain Topogr. 2003; 15(3):165-71. DOI: 10.1023/a:1022606200636. View

13.

Schneider A, Leigh M, Adams P, Nanakul R, Chechi T, Olichney J . Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol. 2013; 27(10):956-63. PMC: 4962861. DOI: 10.1177/0269881113494105. View

14.

Berry-Kravis E, Lindemann L, Jonch A, Apostol G, Bear M, Carpenter R . Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2017; 17(4):280-299. PMC: 6904225. DOI: 10.1038/nrd.2017.221. View

15.

Jonak C, Lovelace J, Ethell I, Razak K, Binder D . Reusable Multielectrode Array Technique for Electroencephalography in Awake Freely Moving Mice. Front Integr Neurosci. 2018; 12:53. PMC: 6213968. DOI: 10.3389/fnint.2018.00053. View

16.

Jonak C, Lovelace J, Ethell I, Razak K, Binder D . Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2020; 138:104794. PMC: 9038039. DOI: 10.1016/j.nbd.2020.104794. View

17.

Ethridge L, White S, Mosconi M, Wang J, Pedapati E, Erickson C . Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome. Mol Autism. 2017; 8:22. PMC: 5463459. DOI: 10.1186/s13229-017-0140-1. View

18.

Kunitomo J, Yoshikawa M, Fushimi M, Kawada A, Quinn J, Oki H . Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. J Med Chem. 2014; 57(22):9627-43. DOI: 10.1021/jm5013648. View

19.

Suzuki K, Harada A, Shiraishi E, Kimura H . In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents. J Pharmacol Exp Ther. 2014; 352(3):471-9. DOI: 10.1124/jpet.114.218552. View

20.

Macek T, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J . A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res. 2018; 204:289-294. DOI: 10.1016/j.schres.2018.08.028. View